ArticlePLoS computational biology2026
Design of an immunogen containing multidimensionally conserved and immunogenic parts of the HIV proteome.
Article in PLoS computational biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Despite decades of research, an effective HIV vaccine or cure has not yet been developed. An important reason is the virus's mutability, which allows it to rapidly evade human immune responses. Often, the virus also takes advantage of epistatic pathways to evolve escape mutations through compensatory effects that allow maintaining its fitness. We used a fitness landscape of HIV, which explicitly considers interactions between mutations, to design an immunogen that contains parts of the proteome that are "multidimensionally" conserved. Based on inferred fitness landscapes, these regions are predicted to be under mutational constraints. Our immunogen also incorporates predicted immunogenic regions and offers broad coverage for the Caucasian population. We further investigate the relative contributions of various proteins in our design and compare properties with other immunogens. We hope that our proposed immunogen will serve as a candidate for experimental evaluation in pre-clinical studies in T cell-based vaccine or immunotherapy contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.